Ivonescimab MOA

Ivonescimab: Most Advanced PD-1/VEGF Bispecific Antibody in Clinical Development the U.S. & EU.* Brings two validated mechanisms in oncology^1,2,3 into ONE novel tetravalent molecule.

For additional information on the HARMONi or the HARMONi-3 clinical trials, please visit clinicaltrials.gov or contact medinfo@smmttx.com

1. Manegold et al., (2016); JTO 12:2.194-207.; 2. Pardoll, Drew M. (2012) Nature Reviews Cancer vol. 12,4 :252-64.; 3. Tamura et al., (2020) Med Oncol 37:2, 10.1007. 4. Zhao Y. et al., (August 2023) eClinicalMedicine vol 62: 102106.; 5. Zhou C. et al., Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 9040.; 6. Zhong T et al., (2022) Journal for ImmunoTherapy of Cancer 10(2) 521. 

Ivonescimab is an investigational therapy that is not approved by any regulatory authority.

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”).